Synagis (Palivizumab)
- Medicine Name: Synagis
- API: Palivizumab
- Dosage Form & Strength: Injections: 50 mg/0.5 mL and 100 mg/1 mL
- Manufactured By: MedImmune, LLC
Synagis is a respiratory syncytial virus (RSV) F protein inhibitor monoclonal antibody used to help prevent a serious lung disease caused by respiratory syncytial virus (RSV) in children:
- born prematurely (at or before 35 weeks) and who are aged 6 months or less at the beginning of the RSV season
- who have a chronic lung complication known as bronchopulmonary dysplasia (BPD), who needed medical therapy within the last 6 months, and who are aged 24 months or less at the beginning of the RSV season
- born with certain types of heart conditions and who are aged 24 months or less at the beginning of the RSV season
Recommended Dosage: The recommended dose of Synagis is 15 mg/kg of body weight, administered intramuscularly (IM) before commencement of the respiratory syncytial virus season and remaining doses administered monthly throughout the respiratory syncytial virus (RSV) season. Children undergoing cardio-pulmonary bypass need to receive an additional dose as quickly as possible after the cardio-pulmonary bypass procedure (even if sooner than a month from the previous dose). Thereafter, doses of Synagis should be used monthly as scheduled.
- Fatal cases of anaphylaxis and anaphylactic shock may occur after initial exposure or re-exposure to Synagis injection. In case anaphylaxis or other significant hypersensitivity reaction occurs, administer suitable medicines (e.g., epinephrine) and provide supportive care as needed. If a mild hypersensitivity reaction occurs, make a clinical judgment regarding cautious readministration of Synagis.
- Synagis is for intramuscular (IM) administration only. As with any intramuscular (IM) injection, Synagis needs to be administered with caution to children with thrombocytopenia or any coagulation disorder.
- Palivizumab may be responsible for interfering with immunological-based respiratory syncytial virus (RSV) diagnostic tests such as some antigen detection-based assays. In addition, it inhibits virus replication in cell culture, and therefore may also interfere with viral culture assays. Assay interference could cause false-negative RSV diagnostic test results. Therefore, diagnostic test results, when obtained, must be used along with clinical findings to guide medical decisions.
- The single-dose vial of Synagis does not contain a preservative. Administration of Synagis injection should occur promptly after dose withdrawal from the vial. The vial should not be re-entered. Discard any unused portion.
What documents are required to import SYNAGIS to India?
SYNAGIS (palivizumab) injections can be imported by patients or government hospitals on the name of the patients only.
The following documentation is required to import the product:
- A valid prescription from a qualified doctor.
- Patients diagnostic reports
- Patients ID proof (issued by the government of India)
The order will be confirmed only after the receipt of:
- A valid prescription from Doctor
- Import permit if applicable
SYNAGIS (palivizumab injections) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input
- On availability of Synagis in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
- Medicine Price.
- Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
- Ensuring 100% transparency.
IPN (Indian Pharma Network) can facilitate the supply of SYNAGIS (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)
Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Synagis 50 mg/100 mg price in India.
We take to guarantee quality and delivery anywhere in the world as per the buyer’s requirements.
Indian Pharma Network is able to source SYNAGIS (Cancer Treatment Medicines) from across the globe and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.
Indian Pharma Network (IPN) is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
What is the Generic Name for the trade name drug Synagis®?
Palivizumab is a Generic Name for the trade name drug Synagis®.
What is the Manufacturer’s Name of Synagis®?
Synagis® is manufactured by MedImmune, LLC.
Where can I get Synagis® at the best price in India?
To get the best Synagis price in India, kindly contact the Indian Pharma Network (a WHO GDP and ISO 9001:2008 certified company). For Synagis®, a medical prescription is needed from a treating physician.
What is the dosage and form of Synagis® supplied?
Synagis® is supplied as single-dose liquid solution vials: 50 mg/0.5 mL & 100 mg/1 mL for intramuscular administration.
What are the most common side effects of Synagis®?
The most common side effects of Synagis® are fever and rash.
How much does Synagis® cost in India?
The cost of Synagis in India can vary. To procure this medicine legally, you can call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.
What are the storage conditions of Synagis®?
Upon receipt and until the time of use, store Synagis between 2°C and 8°C (36°F and 46°F) in its original container. Never freeze it. Avoid using it beyond the expiration date.
Is it safe to buy Synagis® online in India?
Yes, one can buy Synagis online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the supply of Synagis® through legal channels.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.